13F Holdings
中文EN

SPRB SPRUCE BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%

Returns

ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$0$697,000
R&D expense$18.13M$12.16M$7.58M$4.10M$5.01M-$430,000$10.84M$21.46M
SG&A expense$5.85M$4.35M$4.41M$7.00M$3.22M$3.12M$3.65M$3.31M
Operating income-$23.98M-$16.51M-$11.99M-$11.10M-$8.23M-$2.69M-$14.49M-$24.07M
Interest expense$1.20M$1.10M$674,000$6,000$19,000$29,000$36,000$56,000
Net income-$24.01M-$16.23M-$12.27M-$14.65M-$8.21M-$2.07M-$14.04M-$23.56M
EBITDA-$23.24M-$15.88M-$11.73M-$11.10M-$8.23M-$2.69M-$14.49M-$24.07M
EPS (basic)-8.51-6.68-8.94—-14.58-3.50-23.95—
EPS (diluted)-8.51-6.68-8.94—-14.58-3.50-23.95—
Weighted avg. shares (diluted)2.82M2.43M1.37M—563,066591,137586,142—
Balance sheet
Cash & equivalents$87.69M$96.30M$54.08M$48.91M$10.67M$16.39M$25.61M$38.79M
Current assets$90.30M$101.15M$55.03M$52.11M$14.52M$20.95M$30.58M$44.21M
Total assets$91.95M$102.85M$56.17M$53.02M$15.31M$21.82M$31.65M$45.21M
Current liabilities$18.71M$10.96M$11.78M$10.09M$9.43M$8.06M$15.67M$15.25M
Short-term debt$4.00M$2.50M$1.00M$0$539,000$943,000$1.34M$1.62M
Long-term debt$3.82M$4.59M$5.46M$0$0$0$0$124,000
Total debt$7.82M$7.09M$6.46M$0$539,000$943,000$1.34M$1.75M
Total liabilities$25.65M$19.12M$21.52M$10.51M$9.93M$8.64M$16.32M$16.39M
Shareholders' equity$66.30M$83.73M$34.65M$42.52M$5.39M$13.18M$15.32M$28.82M
Net debt-$79.87M-$89.20M-$47.62M-$48.91M-$10.13M-$15.44M-$24.27M-$37.04M
Shares outstanding2.87M2.75M1.37M1.37M563,491563,04242.23M563,042
Cash flow statement
Operating cash flow-$13.76M-$22.12M-$8.73M-$6.46M-$5.32M-$8.83M-$12.73M-$20.68M
Capital expenditure$0$135,000$10,000—$0$0$0$0
Free cash flow-$13.76M-$22.25M-$8.74M—-$5.32M-$8.83M-$12.73M-$20.68M
Investing cash flow$0-$135,000-$10,000—$0$0$0$0
Financing cash flow$5.16M$64.47M$13.92M$44.69M-$402,000-$400,000-$411,000-$625,000
Depreciation & amortization$738,000$631,000$252,000$5,000$3,000$7,000$6,000$9,000
Stock-based compensation$1.10M$871,000$689,000$1.69M$415,000-$77,000$544,000$961,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.